1. Home
  2. ATAI

as 07-09-2025 11:31am EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Founded: 2018 Country:
Germany
Germany
Employees: N/A City: BERLIN
Market Cap: 444.7M IPO Year: 2021
Target Price: $11.00 AVG Volume (30 days): 5.6M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.91 EPS Growth: N/A
52 Week Low/High: $1.03 - $2.98 Next Earning Date: 08-12-2025
Revenue: $1,863,000 Revenue Growth: 572.56%
Revenue Growth (this year): 554.22% Revenue Growth (next year): -81.02%

ATAI Daily Stock ML Predictions

Share on Social Networks: